• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Secondary Prevention Medications Post Coronary Artery Bypass Grafting Surgery-A Literature Review.

作者信息

Dimitriadis Stavros, Qian Evelyn, Irvine Amy, Harky Amer

机构信息

12205Medical Sciences Division, University of Oxford, Oxford, United Kingdom.

Department of Cardiothoracic Surgery, 8959Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.

出版信息

J Cardiovasc Pharmacol Ther. 2021 Jul;26(4):310-320. doi: 10.1177/1074248420987445. Epub 2021 Jan 29.

DOI:10.1177/1074248420987445
PMID:33514291
Abstract

Secondary prevention after coronary artery bypass graft (CABG) surgery is imperative in slowing the progression of atherosclerosis in both native and grafted vessels. Aspirin and statins remain the key medications for all patients without significant contraindications. The evidence for dual antiplatelet therapy with clopidogrel is less convincing, but there is hope for newer antiplatelet agents, such as ticagrelor. Meanwhile, β-blockers and angiotensin converting enzyme inhibitors might only offer benefits to specific sub-groups. Post-CABG patients appear to have different medication needs to the general cardiovascular patient and respond differently. In this review, we cover the drug regimens proposed by recent guidelines and the evidence behind their use. Assessing the evidence behind these recommendations, we find that there is an unmet need in some areas for robust population-specific evidence. We hope that future research will address this gap.

摘要

相似文献

1
Secondary Prevention Medications Post Coronary Artery Bypass Grafting Surgery-A Literature Review.
J Cardiovasc Pharmacol Ther. 2021 Jul;26(4):310-320. doi: 10.1177/1074248420987445. Epub 2021 Jan 29.
2
Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.冠状动脉搭桥术后预防性心血管药物治疗的评估
Pharmacotherapy. 2014 May;34(5):464-72. doi: 10.1002/phar.1380.
3
A Meta-Analysis Comparing Aspirin Alone Versus Dual Antiplatelet Therapy for the Prevention of Venous Graft Failure Following Coronary Artery Bypass Surgery.一项比较单独应用阿司匹林与双联抗血小板治疗预防冠状动脉旁路移植术后静脉移植物失败的荟萃分析。
Cardiovasc Revasc Med. 2020 Jun;21(6):792-796. doi: 10.1016/j.carrev.2019.10.022. Epub 2019 Oct 25.
4
Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial.替格瑞洛联合阿司匹林、替格瑞洛单药或阿司匹林单药对冠状动脉旁路移植术后 1 年大隐静脉桥通畅率的影响:一项随机临床试验。
JAMA. 2018 Apr 24;319(16):1677-1686. doi: 10.1001/jama.2018.3197.
5
Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization.冠状动脉血运重建后最佳药物治疗对 10 年死亡率的影响。
J Am Coll Cardiol. 2021 Jul 6;78(1):27-38. doi: 10.1016/j.jacc.2021.04.087.
6
Socioeconomic Factors, Secondary Prevention Medication, and Long-Term Survival After Coronary Artery Bypass Grafting: A Population-Based Cohort Study From the SWEDEHEART Registry.社会经济因素、二级预防药物治疗与冠状动脉旁路移植术后的长期生存:来自 SWEDEHEART 注册登记研究的一项基于人群的队列研究。
J Am Heart Assoc. 2020 Mar 3;9(5):e015491. doi: 10.1161/JAHA.119.015491. Epub 2020 Mar 2.
7
A systematic review of guidelines for dual antiplatelet therapy in coronary artery bypass graft.冠状动脉旁路移植术中双重抗血小板治疗指南的系统评价
Eur J Clin Invest. 2021 Jan;51(1):e13405. doi: 10.1111/eci.13405. Epub 2020 Sep 25.
8
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.心肌梗死后的长期抗血小板治疗:PEGASUS-TIMI 54研究的启示
Heart. 2016 May 15;102(10):783-9. doi: 10.1136/heartjnl-2015-307858. Epub 2016 Feb 8.
9
Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome.优化药物治疗以进行非侵入性管理的急性冠状动脉综合征二级预防。
Med J Aust. 2014 Nov 17;201(10):S100-5. doi: 10.5694/mja14.01155.
10
Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.卡塔尔急性冠状动脉综合征(ACS)患者出院时基于证据的二级预防药物的使用情况。
Curr Vasc Pharmacol. 2016;14(4):394-403. doi: 10.2174/1570161114666160226150336.

引用本文的文献

1
Pattern Changes in the Heart Rate Variability of Patients Undergoing Coronary Artery Bypass Grafting Surgery.冠状动脉旁路移植手术患者心率变异性的模式变化
Cardiol Res Pract. 2022 Apr 30;2022:1455025. doi: 10.1155/2022/1455025. eCollection 2022.